Imagine if the bacteria that usually cause implant infections could be hacked to work for us instead. Instead of fighting them with antibiotics, this tech uses tiny biological delivery vehicles to reprogram those bacteria to grow new bone. It's like turning a home intruder into a construction worker who repairs your body from the inside.
Implant-associated infections often lead to device rejection and are resistant to standard antibiotic treatments. This creates a high risk of surgical failure and poor patient health outcomes.
Injectable bio-hydrogels and implant coatings combined with engineered liposomes and bacteriophages to reprogram bacteria for protein production.
If you are a dental implant manufacturer dealing with high rates of peri-implant infection and device rejection — this project developed implant coatings that transform biofilms into tissue-regenerating matrices. This reduces the risk of failure and improves patient health outcomes.
If you are a medical device SME dealing with permanent transcutaneous bone implant failures — this project developed injectable bio-hydrogels that recruit cells and stimulate bone growth. This allows for minimally invasive delivery to treat infections while regenerating hard tissue.
If you are a biomaterials developer dealing with the limitations of standard antibiotic regimens against resilient bacterial communities — this project developed functionalized bio-hydrogels and engineered phages. This creates a new way to produce specific proteins in vivo for tissue repair.
Based on available project data, there is no specific information regarding the cost or pricing of the developed hydrogels and coatings.
The project involves 2 SMEs and a total industry ratio of 29%, suggesting a path toward industrialization, though specific scaling data is not provided.
Based on available project data, the IP and licensing terms are not disclosed, but the project is developing new methodologies in implant technology.
The technology is designed as injectable materials or implant coatings, allowing for minimally invasive delivery into the target site.
The project period runs from 2023-04-01 to 2027-03-31, with validation planned in two animal models.
The consortium is a lean, interdisciplinary group of 7 partners across 5 countries. With a 29% industry ratio including 2 SMEs, the project balances academic research (2 universities, 3 research centers) with commercial application, ensuring that the biological breakthroughs are grounded in industrial feasibility.
Contact the Consiglio Nazionale delle Ricerche (CNR) in Italy
Contact us to connect with the BIOACTION consortium for licensing opportunities.
